Use of Ultrashort Columns for Therapeutic Protein Separations. Part 1: Theoretical Considerations and Proof of Concept.


Journal

Analytical chemistry
ISSN: 1520-6882
Titre abrégé: Anal Chem
Pays: United States
ID NLM: 0370536

Informations de publication

Date de publication:
26 01 2021
Historique:
pubmed: 18 12 2020
medline: 20 2 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Due to the particular elution mechanism observed with large solutes (e.g., proteins) in liquid chromatography, column length has less impact in controlling their retention compared to small solutes. Moreover, long columns-in theory-just broaden the peaks of large solutes since a great part of the column only acts as void (extra) volume. Such a theory suggests that using very short columns should result in comparable separation quality versus using long columns and make it possible to perform faster (high-throughput) analyses. Therefore, the elution behavior of various therapeutic monoclonal antibodies and their fragments (25-150 kDa) has been investigated using modern instrumentation and column formats. The possibilities offered by narrow-bore columns packed with state-of-the-art 2.7 μm superficially porous particles with 5, 50, 100, and 150 mm lengths have been compared. In particular, the impact of gradient steepness and column length on separation efficiency was evaluated. Using 5 mm × 2.1 mm columns, it has become possible to separate antibody fragments and antibody-drug conjugate species in less than 30 s. Such fast methods can be very useful for high-throughput screening purposes in biopharmaceutical industries.

Identifiants

pubmed: 33332095
doi: 10.1021/acs.analchem.0c04082
doi:

Substances chimiques

Antibodies, Monoclonal 0
Immunoconjugates 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1277-1284

Auteurs

Szabolcs Fekete (S)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva 4, Switzerland.

Balázs Bobály (B)

Research and Development Biopharmaceuticals, Solvias AG, Römerpark 2, 4303 Kaiseraugst, Switzerland.

Jennifer M Nguyen (JM)

Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757-3696, United States.

Alain Beck (A)

Center of Immunology Pierre Fabre, 5 Avenue Napole'on III, BP 60497, 74160 Saint-Julien-en-Genevois, France.

Jean-Luc Veuthey (JL)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva 4, Switzerland.

Kevin Wyndham (K)

Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757-3696, United States.

Matthew A Lauber (MA)

Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757-3696, United States.

Davy Guillarme (D)

Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva 4, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH